Cancer Drug Fund to gain £160m
NHS England has pledged a £160m boost over two years for the Cancer Drugs Fund. The decision should give more patients access to innovative drugs that are not routinely available on the NHS.
Posted: 28 August 2014
Two new drugs are being added to the Fund – enzalutamide for prostate cancer and lenalidomide for a group of patients with myelodysplastic syndrome, a rare blood condition.
With an annual budget of £200m, now rising by 40% to £280m, the Fund has delivered important benefits for more than 55,000 patients since it began in 2010. Professor Peter Clark, Chair of the Cancer Drugs Fund, has written to NHS England Chief Executive Simon Stevens recommending CDF’s panel of experts re-evaluate a number of drugs currently on the list, making evidence-based decisions about what will deliver greatest benefit to patients. NHS England has accepted and agreed the proposals.
Professor Clark, said, ‘we must re-evaluate some of the drugs on the list. This is absolutely the right thing to do for patients, and I am pleased Simon Stevens has accepted my recommendations’.
Simon Stevens, NHS England’s Chief Executive, said, ‘Since its inception, The Cancer Drugs Fund has successfully enabled the funding of new cancer medicines for tens of thousands of patients in England. We want to build on that success by expanding funding again this year to enable cancer patients to access innovative effective new treatments.
‘Within this extra funding we want to ensure the drugs provide maximum benefits to patients and that the CDF incentivises responsible pricing by drug companies. We want to create a sustainable Cancer Drugs Fund that will ensure patients don’t miss out on innovative treatments that are on the horizon’.